Qaasid News

Download Our App

Category: 3. Business

  • Visa Stock’s Value Score Sinks Even As Wall Street Sees A ‘High-Quality Compounder’ Ready To Rebound

    Visa Stock’s Value Score Sinks Even As Wall Street Sees A ‘High-Quality Compounder’ Ready To Rebound

    Visa Inc. is currently presenting a stark contrast between its quantitative technical metrics and Wall Street’s fundamental analysis. While the stock is down 13.82% year-to-date, leading to a deteriorating value profile, prominent analysts are doubling down on the payments giant’s long-term upside.

    Over the past week, Visa’s Benzinga Edge’s Stock Rankings‘ value score fell from 10.28 to a bottom-tier 10.10. This metric evaluates a stock’s relative worth by comparing its market price to fundamental measures of the company’s assets, earnings, sales, and operating performance.

    Don’t Miss:

    Furthermore, the company’s price trend indicators show downward movement across short, medium, and long-term timeframes. Currently trading with a P/E ratio of 28.38, as per Benzinga, Visa also shows weakness in its price movement patterns, reflected by a low momentum score of 15.71.

    Benzinga Edge’s Stock Rankings for V.

    Freedom Capital Markets upgraded Visa from Hold to Buy in a February 2026 report, raising its price target to $375 per share, representing a 24% upside from the current level, based on earnings resilience and capital return.

    The firm highlighted Visa’s strong fundamentals, including a 15% year-over-year revenue increase to $10.9 billion.

    Freedom Capital On Visa
    Freedom Capital On Visa

    Trending: This Startup Thinks It Can Reinvent the Wheel — Literally

    Similarly, despite these bearish technical signals, Baird maintained an “Outperform” rating alongside a $425 price target, which represents a 40.62% upside from the current level. The firm explicitly labeled the stock a “high-quality compounder” with an attractive valuation setup.

    Baird also noted that Visa’s $500 million litigation escrow funding effectively acts as a buyback of approximately 1.4 million shares.

    Baird On Visa.
    Baird On Visa.

    The bullish Wall Street sentiment is anchored in Visa’s core operational strength. Even as its value and momentum scores drop, Visa boasts an exceptional Benzinga Edge quality score of 92.76.

    See Also: The ‘ChatGPT of Marketing’ Just Opened a $0.91/Share Round — 10,000+ Investors Are Already In

    This ranking highlights the company’s strong operational efficiency and financial health relative to peers. Combined with strategic blockchain expansions like its recent entry into the Canton Network, analysts remain highly confident in Visa’s ability to rebound.

    Continue Reading

  • BNP Paribas FX Overhaul Links CLS Upgrade To Valuation Opportunity

    BNP Paribas FX Overhaul Links CLS Upgrade To Valuation Opportunity

    Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

    • BNP Paribas has adopted CLS’s Cross Currency Swaps service, updating how it manages FX settlement risk and operations.

    • The move brings the bank’s cross currency swap settlements into a centralised service designed to reduce settlement risk and improve liquidity usage.

    • This shift marks a change in BNP Paribas’ FX infrastructure at a time of elevated market volatility and evolving regulatory expectations.

    For investors following BNP Paribas (ENXTPA:BNP), this operational upgrade comes with the shares around €83.3 and a 1 year return of 33.5%. Over 3 years the stock has returned 82.9%, and over 5 years 129.0%. This performance highlights how the bank’s profile has developed across multiple market cycles.

    The CLS Cross Currency Swaps service could matter for you because it targets core plumbing in FX and funding operations, including settlement risk and liquidity usage. As infrastructure like this embeds over time, BNP Paribas’ ability to support complex cross border flows and client hedging needs may be an increasingly important part of its competitive position.

    Stay updated on the most important news stories for BNP Paribas by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on BNP Paribas.

    ENXTPA:BNP Earnings & Revenue Growth as at Apr 2026

    We’ve flagged 4 risks for BNP Paribas. See which could impact your investment.

    • ✅ Price vs Analyst Target: At €83.3 versus a consensus target of about €101.35, the shares sit roughly 18% below where analysts cluster.

    • ✅ Simply Wall St Valuation: The shares are described as trading about 59.9% below estimated fair value, pointing to a wide valuation gap.

    • ❌ Recent Momentum: The 30 day return of about 4.3% decline shows short term pressure despite the longer term track record.

    There is only one way to know the right time to buy, sell or hold BNP Paribas. Head to Simply Wall St’s company report for the latest analysis of BNP Paribas’s Fair Value.

    • 📊 The CLS upgrade focuses on FX settlement plumbing, which sits at the heart of how BNP Paribas handles cross currency funding and client flows.

    • 📊 Watch how management reports on settlement efficiency, liquidity usage, and any cost or balance sheet impacts linked to the new setup.

    • ⚠️ Existing risk flags around bad loans, funding mix, and bad loan allowances mean investors may want to see whether operational gains are matched by balance sheet discipline.

    For the full picture including more risks and rewards, check out the complete BNP Paribas analysis. Alternatively, you can check out the community page for BNP Paribas to see how other investors believe this latest news will impact the company’s narrative.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include BNP.PA.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Brookfield Corporation Has Become the Next Berkshire Hathaway

    Brookfield Corporation Has Become the Next Berkshire Hathaway

    Berkshire Hathaway (NYSE: BRKA)(NYSE: BRKB) has built a record that is nothing short of impressive, with the stock dramatically outperforming the S&P 500 index (SNPINDEX: ^GSPC) over the long term. A key part of the industrial conglomerate’s success is its business model. Brookfield Corporation (NYSE: BN) is trying to use that same model. Here’s what you need to know about this Canadian investment giant.

    Berkshire Hathaway is often classified as an insurance company. That makes sense, since it does operate a number of large insurance businesses. However, the insurance operations are really the foundation on which it has built itself into a massive conglomerate. When you step back and look at the big picture, Berkshire Hathaway was really Warren Buffett’s investment vehicle.

    Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »

    Image source: The Motley Fool.

    The secret to Buffett’s success was his decision to use the float from insurance premiums to invest in companies, either directly buying them or simply buying large amounts of their stock. This is the basic approach that Brookfield Corporation is taking after making several changes to its business.

    Those changes included spinning off its asset management business (it continues to own a stake in Brookfield Asset Management (NYSE: BAM)) and building an insurance operation. Notably, Brookfield Corporation already oversees a number of publicly traded companies that invest in key focus areas, including renewable power, infrastructure, and private equity. It also operates private investment vehicles in real estate and credit.

    Basically, Brookfield Corporation has already turned itself into the next Berkshire Hathaway, with a slightly different twist. At its core, the company is using the same investment-led insurance model that has been so successful for Berkshire Hathaway. However, in practice, it is making investments using a much broader collection of controlled investment vehicles. And it might be an even better approach.

    Berkshire Hathaway is a complicated company to understand because of the massive conglomeration of very different businesses it owns. Brookfield Corporation is perhaps even more difficult to understand because it applies its investment approach across a range of public and private companies. That said, the use of public companies makes it easier to track what Brookfield Corporation is doing and how its investment decisions are performing, since you can simply look at each of the publicly traded companies it oversees if you want to keep tabs on what is going on. Berkshire Hathaway’s investment decisions and results are a lot more opaque, with the company often lumping the results of its controlled businesses into groups when reporting earnings.

    For many, Brookfield Corporation could be a better option than Berkshire Hathaway. That said, Brookfield Corporation’s business shift is relatively new, so it still needs to prove it can successfully use Berkshire Hathaway’s investment-led insurance model. But, given Brookfield Corporation’s over 125 year history of growth, it seems like a worthwhile risk for those hoping to find the next Berkshire Hathaway.

    Before you buy stock in Brookfield Corporation, consider this:

    The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Brookfield Corporation wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

    Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $532,066!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,087,496!*

    Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 185% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

    See the 10 stocks »

    *Stock Advisor returns as of April 4, 2026.

    Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Brookfield, Brookfield Asset Management, and Brookfield Corporation. The Motley Fool has a disclosure policy.

    Brookfield Corporation Has Become the Next Berkshire Hathaway was originally published by The Motley Fool

    Continue Reading

  • SETDB1 modulates neuroinflammation in the mouse cortex by regulating neuronal P2rx7 expression

    SETDB1 modulates neuroinflammation in the mouse cortex by regulating neuronal P2rx7 expression

  • Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry – novel perspectives on brain disorders. Nat Rev Neurol. 2019;15:317–28.

    Article 
    PubMed 

    Google Scholar 

  • Welcome MO, Mastorakis NE. Stress-induced blood brain barrier disruption: Molecular mechanisms and signaling pathways. Pharmacol Res. 2020;157:104769.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22–34.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Torres-Berrio A, Estill M, Patel V, Ramakrishnan A, Kronman H, Minier-Toribio A, et al. Mono-methylation of lysine 27 at histone 3 confers lifelong susceptibility to stress. Neuron. 2024;112:2973–89.e10.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Padeken J, Methot SP, Gasser SM. Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance. Nat Rev Mol Cell Biol. 2022;23:623–40.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang DY, Kosowan J, Samsom J, Leung L, Zhang KL, Li YX, et al. Inhibition of the G9a/GLP histone methyltransferase complex modulates anxiety-related behavior in mice. Acta Pharmacol Sin. 2018;39:866–74.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Tan SL, Nishi M, Ohtsuka T, Matsui T, Takemoto K, Kamio-Miura A, et al. Essential roles of the histone methyltransferase ESET in the epigenetic control of neural progenitor cells during development. Development. 2012;139:3806–16.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zhu Y, Sun D, Jakovcevski M, Jiang Y. Epigenetic mechanism of SETDB1 in brain: implications for neuropsychiatric disorders. Transl Psychiatry. 2020;10:115.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jiang Y, Jakovcevski M, Bharadwaj R, Connor C, Schroeder FA, Lin CL, et al. Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B. J Neurosci. 2010;30:7152–67.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li J, Zheng S, Dong Y, Xu H, Zhu Y, Weng J, et al. Histone Methyltransferase SETDB1 Regulates the Development of Cortical Htr3a-Positive Interneurons and Mood Behaviors. Biol Psychiatry. 2023;93:279–90.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Rowe HM, Jakobsson J, Mesnard D, Rougemont J, Reynard S, Aktas T, et al. KAP1 controls endogenous retroviruses in embryonic stem cells. Nature. 2010;463:237–40.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021;595:309–14.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol. 2006;176:7636–44.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Chandrasekaran S, Espeso-Gil S, Loh YE, Javidfar B, Kassim B, Zhu Y, et al. Neuron-specific chromosomal megadomain organization is adaptive to recent retrotransposon expansions. Nat Commun. 2021;12:7243.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Barden N, Harvey M, Gagne B, Shink E, Tremblay M, Raymond C, et al. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:374–82.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lucae S, Salyakina D, Barden N, Harvey M, Gagne B, Labbe M, et al. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet. 2006;15:2438–45.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kristof Z, Gal Z, Torok D, Eszlari N, Sutori S, Erdelyi-Hamza B, et al. Variation along P2RX7 interacts with early traumas on severity of anxiety suggesting a role for neuroinflammation. Sci Rep. 2023;13:7757.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Troubat R, Leman S, Pinchaud K, Surget A, Barone P, Roger S, et al. Brain immune cells characterization in UCMS exposed P2X7 knock-out mouse. Brain Behav Immun. 2021;94:159–74.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • von Muecke-Heim IA, Ries C, Urbina L, Deussing JM. P2X7R antagonists in chronic stress-based depression models: a review. Eur Arch Psychiatry Clin Neurosci. 2021;271:1343–58.

    Article 

    Google Scholar 

  • Sidoryk-Wegrzynowicz M, Struzynska L. Astroglial and microglial purinergic P2X7 receptor as a major contributor to neuroinflammation during the course of multiple sclerosis. Int J Mol Sci. 2021;22:8404.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • He Y, Taylor N, Fourgeaud L, Bhattacharya A. The role of microglial P2X7: modulation of cell death and cytokine release. J Neuroinflammation. 2017;14:135.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Miras-Portugal MT, Sebastian-Serrano A, de Diego Garcia L, Diaz-Hernandez M. Neuronal P2X7 receptor: involvement in neuronal physiology and pathology. J Neurosci. 2017;37:7063–72.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ohishi A, Keno Y, Marumiya A, Sudo Y, Uda Y, Matsuda K, et al. Expression level of P2X7 receptor is a determinant of ATP-induced death of mouse cultured neurons. Neuroscience. 2016;319:35–45.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sebastian-Serrano A, Engel T, de Diego-Garcia L, Olivos-Ore LA, Arribas-Blazquez M, Martinez-Frailes C, et al. Neurodevelopmental alterations and seizures developed by mouse model of infantile hypophosphatasia are associated with purinergic signalling deregulation. Hum Mol Genet. 2016;25:4143–56.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shin YH, Kim M, Kim N, Choi SK, Namkoong E, Choi SY, et al. Epigenetic alteration of the purinergic type 7 receptor in salivary epithelial cells. Biochem Biophys Res Commun. 2015;466:704–10.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jimenez-Mateos EM, Arribas-Blazquez M, Sanz-Rodriguez A, Concannon C, Olivos-Ore LA, Reschke CR, et al. microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus. Sci Rep. 2015;5:17486.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Garcia-Huerta P, Diaz-Hernandez M, Delicado EG, Pimentel-Santillana M, Miras-Portugal MT, Gomez-Villafuertes R. The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system. J Biol Chem. 2012;287:44628–44.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 Receptor in Infection and Inflammation. Immunity. 2017;47:15–31.

    Article 
    PubMed 

    Google Scholar 

  • Bennett MR. Synaptic P2X7 receptor regenerative-loop hypothesis for depression. Aust N Z J Psychiatry. 2007;41:563–71.

    Article 
    PubMed 

    Google Scholar 

  • Vitureira N, Rafael A, Abudara V. P2X7 receptors and pannexin1 hemichannels shape presynaptic transmission. Purinergic Signal. 2024;20:223–36.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Munoz FM, Gao R, Tian Y, Henstenburg BA, Barrett JE, Hu H. Neuronal P2X7 receptor-induced reactive oxygen species production contributes to nociceptive behavior in mice. Sci Rep. 2017;7:3539.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fellin T, Pozzan T, Carmignoto G. Purinergic receptors mediate two distinct glutamate release pathways in hippocampal astrocytes. J Biol Chem. 2006;281:4274–84.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jiang Y, Loh YE, Rajarajan P, Hirayama T, Liao W, Kassim BS, et al. The methyltransferase SETDB1 regulates a large neuron-specific topological chromatin domain. Nat Genet. 2017;49:1239–50.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chen L, Faas GC, Ferando I, Mody I. Novel insights into the behavioral analysis of mice subjected to the forced-swim test. Transl Psychiatry. 2015;5:e551.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, et al. Neuroinflammation and depression: A review. Eur J Neurosci. 2021;53:151–71.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kato M, Takemoto K, Shinkai Y. A somatic role for the histone methyltransferase Setdb1 in endogenous retrovirus silencing. Nat Commun. 2018;9:1683.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • He J, Babarinde IA, Sun L, Xu S, Chen R, Shi J, et al. Identifying transposable element expression dynamics and heterogeneity during development at the single-cell level with a processing pipeline scTE. Nat Commun. 2021;12:1456.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu X, Liu Z, Wu Z, Ren J, Fan Y, Sun L, et al. Resurrection of endogenous retroviruses during aging reinforces senescence. Cell. 2023;186:287–304.e26.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Liu S, Heumuller SE, Hossinger A, Muller SA, Buravlova O, Lichtenthaler SF, et al. Reactivated endogenous retroviruses promote protein aggregate spreading. Nat Commun. 2023;14:5034.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sun W, Cornwell A, Li J, Peng S, Osorio MJ, Aalling N, et al. SOX9 Is an astrocyte-specific nuclear marker in the adult brain outside the neurogenic regions. J Neurosci. 2017;37:4493–507.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li P, Wei J, Zhu Y. CellGO: a novel deep learning-based framework and webserver for cell-type-specific gene function interpretation. Brief Bioinform. 2023;25:bbad417.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Witt I, Straub N, Kaufer NF, Gross T. The CAGTCACA box in the fission yeast Schizosaccharomyces pombe functions like a TATA element and binds a novel factor. EMBO J. 1993;12:1201–8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cho MJ, Lee DG, Lee JW, Hwang B, Yoon SJ, Lee SJ, et al. Endothelial PTP4A1 mitigates vascular inflammation via USF1/A20 axis-mediated NF-kappaB inactivation. Cardiovasc Res. 2023;119:1265–78.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36:2628–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Guo M, Zhu J, Hu Z, Wang Q, Songyang Z, Xiong Y. Histone mRNA polyadenylation-mediated inflammation underlies various virus infections and cancers. J Med Virol. 2023;95:e28826.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Polykratis A, Martens A, Eren RO, Shirasaki Y, Yamagishi M, Yamaguchi Y, et al. A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain. Nat Cell Biol. 2019;21:731–42.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2:725–34.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pastuzyn ED, Day CE, Kearns RB, Kyrke-Smith M, Taibi AV, McCormick J, et al. The neuronal gene arc encodes a repurposed retrotransposon Gag protein that mediates intercellular RNA transfer. Cell. 2018;172:275–88.e18.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Manghera M, Douville RN. Endogenous retrovirus-K promoter: a landing strip for inflammatory transcription factors? Retrovirology. 2013;10:16.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kwon DN, Lee YK, Greenhalgh DG, Cho K. Lipopolysaccharide stress induces cell-type specific production of murine leukemia virus type-endogenous retroviral virions in primary lymphoid cells. J Gen Virol. 2011;92:292–300.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wu B, Peng L, Xie J, Zou L, Zhu Q, Jiang H, et al. The P2X(7) receptor in dorsal root ganglia is involved in HIV gp120-associated neuropathic pain. Brain Res Bull. 2017;135:25–32.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Yang R, Yu T, Kou X, Gao X, Chen C, Liu D, et al. Tet1 and Tet2 maintain mesenchymal stem cell homeostasis via demethylation of the P2rX7 promoter. Nat Commun. 2018;9:2143.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Parisi C, Napoli G, Amadio S, Spalloni A, Apolloni S, Longone P, et al. MicroRNA-125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ. 2016;23:531–41.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Engel T, Brennan GP, Sanz-Rodriguez A, Alves M, Beamer E, Watters O, et al. A calcium-sensitive feed-forward loop regulating the expression of the ATP-gated purinergic P2X7 receptor via specificity protein 1 and microRNA-22. Biochim Biophys Acta Mol Cell Res. 2017;1864:255–66.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hashimoto-Hill S, Friesen L, Kim M, Kim CH. Contraction of intestinal effector T cells by retinoic acid-induced purinergic receptor P2X7. Mucosal Immunol. 2017;10:912–23.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Shoulders CC, Naoumova RP. USF1 implicated in the aetiology of familial combined hyperlipidaemia and the metabolic syndrome. Trends Mol Med. 2004;10:362–5.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Albalawi F, Lu W, Beckel JM, Lim JC, McCaughey SA, Mitchell CH. The P2X7 receptor primes IL-1beta and the NLRP3 inflammasome in astrocytes exposed to mechanical strain. Front Cell Neurosci. 2017;11:227.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Illes P. P2X7 receptors amplify CNS damage in neurodegenerative diseases. Int J Mol Sci. 2020;21:5996.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Tao C, Zhang GW, Sun WJ, Huang JJ, Zhang LI, Tao HW. Excitation-inhibition imbalance in medial preoptic area circuits underlies chronic stress-induced depression-like states. Nat Commun. 2024;15:8575.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018;43:2154–60.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Beltran-Lobo P, Hughes MM, Troakes C, Croft CL, Rupawala H, Jutzi D, et al. P2X(7)R influences tau aggregate burden in human tauopathies and shows distinct signalling in microglia and astrocytes. Brain Behav Immun. 2023;114:414–29.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chen R, Ishak CA, De Carvalho DD. Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis. Cancer Discov. 2021;11:2707–25.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zhou J, Geng Y, Su T, Wang Q, Ren Y, Zhao J, et al. NMDA receptor-dependent prostaglandin-endoperoxide synthase 2 induction in neurons promotes glial proliferation during brain development and injury. Cell Rep. 2022;38:110557.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lima-Junior DS, Krishnamurthy SR, Bouladoux N, Collins N, Han SJ, Chen EY, et al. Endogenous retroviruses promote homeostatic and inflammatory responses to the microbiota. Cell. 2021;184:3794–811.e19.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Karlsson H, Bachmann S, Schroder J, McArthur J, Torrey EF, Yolken RH. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci USA. 2001;98:4634–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Balestrieri E, Arpino C, Matteucci C, Sorrentino R, Pica F, Alessandrelli R, et al. HERVs expression in autism spectrum disorders. PLoS One. 2012;7:e48831.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Giuliano CJ, Lin A, Girish V, Sheltzer JM. Generating single cell-derived knockout clones in mammalian cells with CRISPR/Cas9. Curr Protoc Mol Biol. 2019;128:e100.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kantzer CG, Boutin C, Herzig ID, Wittwer C, Reiss S, Tiveron MC, et al. Anti-ACSA-2 defines a novel monoclonal antibody for prospective isolation of living neonatal and adult astrocytes. Glia. 2017;65:990–1004.

    Article 
    PubMed 

    Google Scholar 

  • Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Caglayan E, Liu Y, Konopka G. Neuronal ambient RNA contamination causes misinterpreted and masked cell types in brain single-nuclei datasets. Neuron. 2022;110:4043–56.e5.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573–87.e29.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jin Y, Tam OH, Paniagua E, Hammell M. TEtranscripts: a package for including transposable elements in differential expression analysis of RNA-seq datasets. Bioinformatics. 2015;31:3593–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

Continue Reading

  • Assessing GDS Holdings (GDS) After Its Strong Multi‑Year Share Price Recovery

    Assessing GDS Holdings (GDS) After Its Strong Multi‑Year Share Price Recovery

    Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

    • If you are wondering whether GDS Holdings at around US$39.91 is still good value after a strong run, this breakdown is designed to help you size up what the current price might be implying.

    • The stock has seen a 1.2% decline over the last 7 days, a 4.7% gain over 30 days, is up 4.1% year to date, 85.8% over 1 year, 123.7% over 3 years, but is 49.0% lower over 5 years. This gives a mixed picture for anyone trying to judge risk and potential.

    • Recent headlines around GDS Holdings have focused on the company’s position in its market and how investors are reassessing the stock after such a strong 1 year and 3 year return profile. That context matters for valuation, because sentiment and expectations often shape how far investors are willing to stretch on price.

    • Despite those moves, GDS Holdings currently records a valuation score of 0 out of 6. The next sections will walk through the key valuation approaches commonly used on this stock and then finish with a more complete way to think about what the current price might mean.

    GDS Holdings scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts those cash flows back to today to estimate what the business might be worth right now.

    For GDS Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in CN¥. The latest twelve month free cash flow is a loss of CN¥727.76 million. Analyst inputs and projections show free cash flow staying negative for several years, then shifting to positive, reaching CN¥467.10 million in 2030, with further projected growth beyond that based on extrapolations.

    When all those projected cash flows are discounted back to today, the DCF model produces an estimated intrinsic value of about CN¥0.59 per share. Compared with the current share price of about US$39.91, this model output characterizes the stock as very overvalued, with an intrinsic discount figure of 6,640.7%.

    Result: OVERVALUED

    Our Discounted Cash Flow (DCF) analysis suggests GDS Holdings may be overvalued by 6640.7%. Discover 59 high quality undervalued stocks or create your own screener to find better value opportunities.

    GDS Discounted Cash Flow as at Apr 2026

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for GDS Holdings.

    For companies that are generating earnings, the P/E ratio is a straightforward way to see how much you are paying for each dollar of profit. Higher growth expectations and lower perceived risk usually support a higher P/E, while slower growth or higher risk tend to justify a lower, more conservative multiple.

    GDS Holdings currently trades on a P/E of 61.47x. That is above the broader IT industry average P/E of 20.08x and also above the peer group average of 50.81x. On the surface, that suggests investors are paying a higher price for the company’s earnings than for many industry peers.

    Simply Wall St’s Fair Ratio for GDS Holdings is 34.26x. This Fair Ratio is a proprietary estimate of what a more appropriate P/E might be, taking into account factors such as earnings growth, industry, profit margins, market cap and specific risks. Because it is tailored to the company, it can provide a more rounded reference point than a simple comparison with peers or the industry alone.

    Comparing the current P/E of 61.47x with the Fair Ratio of 34.26x points to the shares trading above that Fair Ratio benchmark.

    Result: OVERVALUED

    NasdaqGM:GDS P/E Ratio as at Apr 2026
    NasdaqGM:GDS P/E Ratio as at Apr 2026

    P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

    Earlier the article mentioned that there is an even better way to understand valuation, so here is Narratives, a simple framework where you set out your story for GDS Holdings, link it to a forecast for revenue, earnings and margins, and arrive at your own fair value that you can compare with the current price.

    On Simply Wall St’s Community page, Narratives are easy to use and widely shared, and they help you decide whether GDS Holdings looks attractive or stretched by showing the gap between your Fair Value and the latest market price. They also update that view automatically when new earnings, guidance or news is released.

    For GDS Holdings, one investor might build a cautious Narrative around heavy debt, slower reported revenue growth from asset sales and pressure on margins, leading to a lower Fair Value near US$35.91. Another might focus on AI data center demand, capital recycling and international expansion, arriving at a higher Fair Value near US$68.63. These two Narratives sit side by side so you can see exactly which assumptions you agree with.

    For GDS Holdings, we will make it really easy for you with previews of two leading GDS Holdings Narratives:

    🐂 GDS Holdings Bull Case

    Fair Value: US$53.72

    Implied discount to Fair Value at the last close of US$39.91: about 26%.

    Revenue growth assumption: 13.90% a year.

    • Focuses on large prepared power capacity in key Chinese markets and an expanding DayOne footprint in Southeast Asia and Europe as support for future AI and digital demand.

    • Highlights use of asset backed securities and C REITs to recycle capital and adjust leverage while keeping growth projects funded.

    • Flags risks around falling average pricing, continued reliance on asset sales, high net debt, delayed AI driven workloads and concentration in large cloud and internet customers.

    🐻 GDS Holdings Bear Case

    Fair Value: US$35.91

    Implied premium to Fair Value at the last close of US$39.91: about 11%.

    Revenue growth assumption: 11.74% a year.

    • Centers on high leverage, exposure to higher funding costs and slower reported revenue and EBITDA as more assets are moved into ABS and C REIT structures.

    • Points to pressure on average monthly service revenue per square meter, higher energy and compliance costs, and uncertainty from regulation, export controls and geopolitical tension.

    • Accepts that long term digital and AI demand, capital recycling options and international expansion could offset some of these pressures if they play out more favorably than expected.

    Do you think there’s more to the story for GDS Holdings? Head over to our Community to see what others are saying!

    NasdaqGM:GDS 1-Year Stock Price Chart
    NasdaqGM:GDS 1-Year Stock Price Chart

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include GDS.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • BYD Weighs Record Overseas Sales Against Domestic Slump And Battery Shift

    BYD Weighs Record Overseas Sales Against Domestic Slump And Battery Shift

    Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

    • BYD (SEHK:1211) reported a 65% jump in overseas unit sales in March, reaching its highest overseas volume in three months.

    • Domestic sales fell for the seventh consecutive month over the same period, highlighting a split between international and home market performance.

    • The company raised its export target for 2026, citing the role of higher oil prices and new international plants in supporting demand.

    • BYD also launched its first major battery upgrade in six years, a development that could influence buyer perception of its vehicles.

    For investors tracking BYD’s mix of growth drivers, the latest numbers underline the contrast between overseas traction and a weaker domestic backdrop. BYD, a major electric vehicle and battery producer, is relying more on global demand at a time when international buyers may be more sensitive to fuel prices and local production footprints.

    The new battery technology and higher export ambitions add fresh variables to watch beyond short term sales swings. The way these changes affect product appeal, pricing dynamics, and regional sales mix may help define the evolving risk profile and earnings quality story around BYD (SEHK:1211).

    Stay updated on the most important news stories for BYD by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on BYD.

    SEHK:1211 1-Year Stock Price Chart

    See which insiders are buying and buying and selling BYD following this latest news.

    For existing and prospective shareholders, BYD’s record overseas sales in March sit against a recent full-year picture where sales reached CNY 803.96b while net income moved to CNY 32.62b and earnings per share dipped to CNY 3.58 from CNY 4.61. That mix, plus a lower proposed final dividend of RMB 0.358 per share, suggests the business is leaning harder on export growth and new technology, such as its first major battery upgrade in six years, at a time when domestic demand is under pressure. Market reaction to this combination of softer earnings, reduced cash returns and stronger export volumes can be a useful read on whether investors are prioritising growth optionality or capital return right now.

    • ⚠️ Pressure on earnings, with net income and EPS below the prior year, may keep some income focused investors cautious about the quality and resilience of profits.

    • ⚠️ A seventh month of weaker domestic sales, alongside a lower proposed dividend, may signal that management has less room to support shareholder payouts if the home market stays soft.

    • 🎁 Record overseas sales in March and a higher 2026 export target point to growing traction in international markets, which may diversify BYD’s revenue base away from China.

    • 🎁 The first major battery upgrade in six years could strengthen product appeal relative to other electric vehicle makers such as Tesla, NIO or XPeng if buyers respond positively to the new technology.

    From here, keep an eye on how quickly overseas volumes scale relative to ongoing domestic softness, and whether the new battery technology shows up in pricing power, order intake or regional sales mix. The progression from proposed to approved dividend later in 2026, and any commentary from the 2025 earnings call, can also help you judge how management is balancing reinvestment with shareholder returns.

    To ensure you’re always in the loop on how the latest news impacts the investment narrative for BYD, head to the community page for BYD to never miss an update on the top community narratives.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include 1211.HK.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Amazon Globalstar Interest Puts Apple Satellite Story Under Fresh Review

    Amazon Globalstar Interest Puts Apple Satellite Story Under Fresh Review

    Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

    • Amazon is exploring a potential acquisition of Globalstar, the satellite operator that underpins Apple’s Emergency SOS and other satellite features.

    • Apple, which holds a significant stake in Globalstar, currently relies on the company’s network to support satellite connectivity on selected iPhone models.

    • A change of control at Globalstar to another large tech company could affect how NasdaqGS:AAPL structures future device features and service agreements.

    For Apple, satellite connectivity has become part of the broader hardware and services story, alongside devices, wearables and digital subscriptions. The tie up with Globalstar helps support Emergency SOS and related services that Apple uses to differentiate certain iPhone models in a crowded smartphone market. In parallel, large technology groups are looking more closely at space based infrastructure as demand for always on connectivity expands.

    If Amazon proceeds with a Globalstar deal, investors in NasdaqGS:AAPL may focus on how Apple responds in terms of contract terms, network redundancy and control over key user experiences. The outcome could influence how Apple approaches future satellite partnerships, capital allocation to connectivity projects and the balance between in house capabilities and external providers over the long term.

    Stay updated on the most important news stories for Apple by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Apple.

    NasdaqGS:AAPL Earnings & Revenue Growth as at Apr 2026

    We’ve flagged 0 risks for Apple. See which could impact your investment.

    For Apple, Amazon’s interest in buying Globalstar goes straight to the heart of how it delivers emergency and satellite features on iPhone. Apple holds a 20% stake in Globalstar and has committed about US$1.5b to its infrastructure, so any ownership change to a large competitor in consumer tech is more than a routine supplier shuffle. Investors are likely to think about whether Apple can preserve priority access, service quality, and economics if Amazon gains control of Globalstar while also building its own satellite operation to rival services like SpaceX’s Starlink. This also sits alongside Apple’s broader approach of leaning on external partners in areas like AI models while keeping the user relationship and overall experience inside its own ecosystem.

    • The possible Globalstar sale fits the existing narrative that Apple uses partnerships to support hardware and services growth, since satellite connectivity has helped differentiate higher end iPhones and support its services story.

    • At the same time, the prospect of Amazon owning Globalstar challenges the idea that supply chain moves are mainly reducing dependence on powerful partners, because a key satellite provider could end up owned by a direct rival to Apple’s devices and services.

    • The current narrative places a lot of weight on AI partnerships and services expansion but does not fully spell out how control of space based connectivity, and a partner like Amazon entering that layer, might affect Apple’s long term bargaining power.

    Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Apple to help decide what it’s worth to you.

    • ⚠️ If Amazon gains control of Globalstar, Apple could face tougher contract negotiations around capacity, pricing, and feature roadmaps for satellite services on iPhone compared with working with a standalone satellite partner.

    • ⚠️ A competitor such as Amazon controlling a critical connectivity layer may increase operational and concentration risk for Apple if there are service disruptions, conflicting priorities, or limited alternatives in the near term.

    • 🎁 Apple’s existing 20% equity stake and US$1.5b investment give it a formal voice in Globalstar deal discussions, which may help secure contract protections and maintain continuity for emergency and connectivity features.

    • 🎁 The scrutiny around this possible deal may prompt Apple to diversify satellite relationships or invest further in alternative connectivity options, which could reduce single partner risk over time.

    From here, keep an eye on any disclosure about Apple’s consent rights, long term capacity agreements, or change of control clauses if Amazon moves ahead with an offer for Globalstar. Watch for signals on whether Apple sticks with Globalstar under new ownership or starts flagging alternative partners or in house projects for satellite support. Commentary from other large players in connectivity, such as Alphabet and Microsoft, on space based infrastructure could also give context for how competitive this layer is becoming. Taken together, these details will help you judge how much control Apple keeps over a feature set that is increasingly tied to safety, reliability, and differentiation for premium devices.

    To ensure you’re always in the loop on how the latest news impacts the investment narrative for Apple, head to the community page for Apple to never miss an update on the top community narratives.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include AAPL.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • ‘Mass layoffs by email might be the new norm’ as Oracle lays off thousands that way

    ‘Mass layoffs by email might be the new norm’ as Oracle lays off thousands that way

    By Weston Blasi

    The cloud-computing and database company began cutting 30,000 jobs on Tuesday

    Oracle this week told some workers in the U.S. and India that their roles were being eliminated.

    Oracle Corp.’s mass layoffs on Tuesday were part of the company’s cost-cutting measures as it continues to build out expensive data centers for powering artificial intelligence.

    But one aspect of the mass layoffs – which were estimated to be as many as 30,000 people – was alerting workers over email at 6 a.m. Eastern that Tuesday would be their last day. It’s not clear if all 30,000 of the reported layoffs occurred on Tuesday, or if more are coming later in the year.

    “After careful consideration of Oracle’s current business needs, we have made the decision to eliminate your role,” an email to one affected employee, obtained by MarketWatch, read.

    Oracle (ORCL) employed an estimated 162,000 people worldwide as of May 2025, and has seen its stock falter this year. Shares of Oracle are down 4.3% over the past month, and down 25% year to date.

    Oracle declined to comment.

    While MarketWatch’s Charles Passy has noted that there’s no such thing as a good layoff, getting let go over email is starting to become a growing trend.

    “It’s not unheard of to lay workers off by email, especially in the tech industry and large corporations,” Peter Duris, CEO and co-founder of Kickresume, a career platform and resume-builder company, told MarketWatch. “There have been quite a few stories in recent years about major companies laying off large numbers of employees by email. Those messages are often described as cold, impersonal and vague about why a role is being cut.”

    Amazon (AMZN) made headlines earlier this year after its planned mass-layoff email was accidentally sent too early, and to the wrong employees.

    Tesla’s (TSLA) Elon Musk famously used “Dear Employee” emails to trim Tesla’s workforce starting in 2024. In that situation, even some bosses were unaware that layoffs were coming, one Tesla employee told MarketWatch in 2024.

    Google (GOOG) (GOOGL)also announced a headcount reduction over email back in 2024.

    While this process may seem impersonal, when really large companies conduct mass layoffs, this is one of the most efficient ways to let thousands of workers know they have been let go. Particularly if they are not all in one location.

    “Letting all these employees know at the same time creates much less administrative work,” Duris said. “This is especially the case when the workers being laid off are based all over the world, in multiple time zones.”

    “It also lets companies cut off access to work email and other platforms immediately after delivering the news, which may help prevent retaliation from angry employees,” he added.

    Besides email, we’ve also seen layoffs over Zoom (ZM) or video calls in recent years. And Duris doesn’t expect those types of layoffs to subside anytime soon.

    “Unfortunately, mass layoffs by email might be the new norm in the tech industry. Similarly, companies are telling employees they’ve lost their jobs over video calls, sometimes with the chat function disabled or with attendees unable to switch their microphones on… some people have even been fired by pre-recorded video messages, leaving them with no way to respond.”

    Read on: Here’s one reason investors shouldn’t get too excited about this week’s stock-market rebound

    -Weston Blasi

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. 

    
  (END) Dow Jones Newswires
    

    
  04-04-26 1125ET
    

    Copyright (c) 2026 Dow Jones & Company, Inc.

    Continue Reading

  • April typically showers stock investors with gains – but this year is no sure bet

    April typically showers stock investors with gains – but this year is no sure bet

    By Mark Hulbert

    Between tax season and early sell-in-May activity, investors shouldn’t count on an April rally

    April may not be the cruelest month – but it is a riskier one.

    Some Wall Street analysts are insisting that April – contrary to its label as the cruelest month – is actually one of the better months for the U.S. stock market.

    Consider that, over the past century, the S&P 500 SPX (or its predecessor index) has gained 1.3% on average in April – close to double the all-month average of 0.7%. But, as the green columns in the chart below indicate, three other months post average returns on par with those of April (shown as No. 4 for the fourth month), with one month, July (or No. 7), significantly better.

    The chart also shows the first half of April being notably strong for stocks. That’s for at least two reasons, according to some of the newsletter editors I regularly monitor. One is the Federal Reserve’s desire to keep economywide liquidity stable at a time when taxpayers are sending potentially large sums to the IRS. Another is that taxpayers can reduce their tax burdens by investing in an IRA before April 15. Much of the additional liquidity and IRA contributions presumably make their way into the stock market.

    These are nice theories, but they are not borne out by the data, as the red columns in the chart show. So while April’s average first-half return is above average, it is not statistically significant.

    Season’s grating

    One caveat that investors should be aware of: April marks the end of the six-month period that is believed to have positive seasonality for stocks. April, therefore, is a month in which some investors look for opportunities to sell rather than wait until May (recall the adage “sell in May and go away”). Last year, for example, Jeffrey Hirsch of the Stock Trader’s Almanac and the Almanac Investor Newsletter, who recommends jumping the gun in this way, exited stocks on April 3 – almost a full month in advance of the usual sell date.

    The bottom line: You may want to remain invested in equities during April or even increase your holdings. If you do, though, it shouldn’t be because of the calendar. Given the year-to-year volatility in monthly returns, April’s advantage over other months is not significant at the 95% confidence level that statisticians often use to assess whether a pattern is genuine. That means it would be too risky for you to bet that April will be a good month for the stock market.

    Mark Hulbert is a regular contributor to MarketWatch. His Hulbert Ratings tracks investment newsletters that pay a flat fee to be audited. He can be reached at mark@hulbertratings.com

    More: A wild first quarter comes to an end: 6 charts that defined a chaotic stretch for stocks

    Also read: Stocks surge, ending a tough March on a high note. But there’s skepticism about the rally.

    -Mark Hulbert

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. 

    
  (END) Dow Jones Newswires
    

    
  04-04-26 1112ET
    

    Copyright (c) 2026 Dow Jones & Company, Inc.

    Continue Reading

  • Risk of Intraoperative Periprosthetic Femoral Fracture According to Cementless Femoral Stem Geometry: A Cohort Study Based on the Radaelli Classification

    Risk of Intraoperative Periprosthetic Femoral Fracture According to Cementless Femoral Stem Geometry: A Cohort Study Based on the Radaelli Classification

    Continue Reading